This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Management according to presentation

Authoring team

Management according to presentation

If the patient presents with urticaria for the first time:

  • the patient should be reassured that the it is not a serious disease and usually self limiting
  • a non-sedating oral antihistamine (e.g. cetirizine, fexofenadine, or loratadine) can be given to control the day time symptoms
  • if itching interferes with sleep an additional sedating antihistamine can be prescribed at night
  • for generalised acute urticaria, a short course of oral corticosteroids (e.g. prednisolone 40 mg daily for 3-5 days) can be given in addition to the oral antihistamine
  • people should be advised to return if there is worsening of symptoms
  • in cases where there is no improvement after 2 weeks of treatment, an alternative non-sedating antihistamine can be tried or should reconsider the diagnosis (1)

In persistent (chronic urticaria):

  • patient should be advised about avoiding possible trigger factors
  • a non-sedating antihistamine to control day time symptoms
  • an additional sedating antihistamine to control nocturnal itching
  • additionally to antihistamine or as a substitute to antihistamine, a topical menthol 1% cream can be used " for 'severe flare-ups' a short course of oral prednisolone (e.g. 40 mg daily 3-5 days) can be given. Repeat of steroids is not recommended (1)

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.